Supernus Pharmaceuticals (SUPN) Assets Average (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 15 years of Assets Average data on file, last reported at $1.5 billion in Q1 2026.

• On a quarterly basis, Assets Average rose 8.77% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 8.77% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, up 6.61% from the prior year.
• Assets Average for Q1 2026 stood at $1.5 billion, up from $1.4 billion in the prior quarter.
• Over the last five years, Assets Average for SUPN reached as high as $1.7 billion in Q1 2023 and fell as low as $1.3 billion in Q4 2023.
• Historically, Assets Average has averaged $1.5 billion across 5 years, with a median of $1.4 billion in 2025.
• Across the five-year window, Assets Average increased 10.53% in 2022 and slipped 26.12% in 2024, its largest moves.
• Year by year, Assets Average stood at $1.7 billion in 2022, then retreated by 24.53% to $1.3 billion in 2023, then rose by 5.77% to $1.4 billion in 2024, then rose by 5.96% to $1.4 billion in 2025, then gained by 2.82% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.